Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by PNPLA3 is a triacylglycerol lipase that mediates triacylglycerol hydrolysis in adipocytes. Additionally we are shipping PNPLA3 Kits (14) and PNPLA3 Proteins (7) and many more products for this protein.
Showing 10 out of 93 products:
Human Polyclonal PNPLA3 Primary Antibody for EIA, WB - ABIN954228
Santoro, Kursawe, DAdamo, Dykas, Zhang, Bale, Calí, Narayan, Shaw, Pierpont, Savoye, Lartaud, Eldrich, Cushman, Zhao, Shulman, Caprio: A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. in Hepatology (Baltimore, Md.) 2010
Show all 3 references for 954228
Human Polyclonal PNPLA3 Primary Antibody for IHC, ELISA - ABIN361184
Kumari, Schoiswohl, Chitraju, Paar, Cornaciu, Rangrez, Wongsiriroj, Nagy, Ivanova, Scott, Knittelfelder, Rechberger, Birner-Gruenberger, Eder, Brown, Haemmerle, Oberer, Lass, Kershaw, Zimmermann et al.: Adiponutrin functions as a nutritionally regulated lysophosphatidic acid acyltransferase. ... in Cell metabolism 2012
Show all 2 references for 361184
Human Polyclonal PNPLA3 Primary Antibody for IHC, WB - ABIN2783569
Wilson, Gardner, Lambie, Commans, Crowther: Characterization of the human patatin-like phospholipase family. in Journal of lipid research 2006
Human Polyclonal PNPLA3 Primary Antibody for ELISA, IHC - ABIN4278479
Steinberg, Kemp, Watt: Adipocyte triglyceride lipase expression in human obesity. in American journal of physiology. Endocrinology and metabolism 2007
The PNPLA3 rs738409 GG genotype is positively associated with hepatic steatosis in Asian patients with chronic hepatitis C.
The study proposes that polymorphisms in the PNPLA3 gene have highly predictive value in the development of nonalcoholic fatty liver disease and are independently associated with the severity of liver histology in patients with NAFLD (show TSC2 Antibodies).
PNPLA3 association with adiposity and the risk of the nonalcoholic fatty liver disease
PNPLA3 gene variant is associated with the risk of developing liver fibrosis and cirrhosis in an Eastern European population.
PNPLA3 acts as a positive modulator of activated human hepatic stellate cells, affecting cytokines secretion.
The results show that in obese patients, the presence of the PNPLA3 p.I148M allele might be associated with greater improvement of hepatic steatosis after bariatric surgery in comparison to carriers of PNPLA3 wild-type alleles. The also lost more weight and had reduced liver fat content.
Fibrosis stages were affected by the PNPLA3 (P = 0.042) and MBOAT7 (show MBOAT7 Antibodies) (P = 0.021) but not by the TM6SF2 polymorphism (P > 0.05). The PNPLA3, TM6SF2, and MBOAT7 (show MBOAT7 Antibodies) variants are associated with increased liver injury. The TM6SF2 variant seems to modulate predominantly hepatic fat accumulation, whereas the MBOAT7 (show MBOAT7 Antibodies) polymorphism is linked to fibrosis. The PNPLA3 polymorphism confers risk of both increased steatosis and fibrosis
PNPLA3 rs738409 (C>G) was associated with the risk of both advanced liver fibrosis and steatosis in patients with chronic hepatitis C, especially among Caucasian populations
we provide evidence to indicate that PNPLA3-mediated retinol release may protect against liver fibrosis by inducing a specific signature of proteins involved in extracellular matrix remodelling
The percentage of the PNPLA3 rs738409 GG genotype in NAFLD (show TSC2 Antibodies) patients was also significantly higher than that in the controls.
Neither ablation nor overexpression of wild-type PNPLA3 affects liver fat content in mice, whereas hepatic overexpression of the human 148M transgene causes steatosis.
PNPLA3 plays a role in remodeling TAG in lipid droplets, as they accumulate in response to food intake
adiponutrin/PNPLA3 is regulated by two key factors of the glycolytic and lipogenic pathways, raising the question of its implication in the metabolism of carbohydrates and lipids
data argue against a role for Pnpla3 loss-of-function in fatty liver disease or metabolic syndrome in mice.
Loss of Pnpla3 does not cause fatty liver, liver enzyme elevation, or insulin (show INS Antibodies) resistance in mice.
Microarray-based gene profiling showed that the expression level of PNPLA3 in hepatocytes is correlated with that of genes associated with the lipogenic pathway such as ME1 (show ME1 Antibodies), SPOT14 (show THRSP Antibodies), and SCD1 (show SCD Antibodies).
data suggest that murine ATGL (show PNPLA2 Antibodies) but not adiponutrin contributes to net adipocyte lipolysis and that ATGL (show PNPLA2 Antibodies) and adiponutrin are oppositely regulated by insulin (show INS Antibodies) both in vitro and in vivo
The protein encoded by this gene is a triacylglycerol lipase that mediates triacylglycerol hydrolysis in adipocytes. The encoded protein, which appears to be membrane bound, may be involved in the balance of energy usage/storage in adipocytes.
, calcium-independent phospholipase A2-epsilon
, patatin-like phospholipase domain-containing protein 3